Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591 in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer

摘要

Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 3 subjects at WCMC. An additional 12 subjects enrolled (7 treated) at participating sub-sites. Reports submitted to WCMC DSMB with recommendation to proceed with enrollment.